Keros Therapeutics Management
Management criteria checks 3/4
Keros Therapeutics' CEO is Jas Seehra, appointed in Dec 2015, has a tenure of 10.08 years. total yearly compensation is $6.27M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.99% of the company’s shares, worth $5.71M. The average tenure of the management team and the board of directors is 5.8 years and 5.8 years respectively.
Key information
Jas Seehra
Chief executive officer
US$6.3m
Total compensation
| CEO salary percentage | 11.14% |
| CEO tenure | 10.1yrs |
| CEO ownership | 1.0% |
| Management average tenure | 5.8yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%
Nov 18
Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
Aug 21Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being
May 29Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point
May 14Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified
May 09Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine
Mar 13Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff
Dec 12We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Nov 20Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
Aug 07Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Jun 10Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?
Apr 23We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Sep 24We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth
Jun 10Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Dec 25Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Sep 08Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07
Aug 04Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Apr 29We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
Jan 24Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth
Oct 10We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely
May 05Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?
Mar 13We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate
Jan 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$64m |
| Jun 30 2025 | n/a | n/a | US$19m |
| Mar 31 2025 | n/a | n/a | US$4m |
| Dec 31 2024 | US$6m | US$699k | -US$187m |
| Sep 30 2024 | n/a | n/a | -US$182m |
| Jun 30 2024 | n/a | n/a | -US$168m |
| Mar 31 2024 | n/a | n/a | -US$160m |
| Dec 31 2023 | US$9m | US$649k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$142m |
| Jun 30 2023 | n/a | n/a | -US$127m |
| Mar 31 2023 | n/a | n/a | -US$116m |
| Dec 31 2022 | US$6m | US$611k | -US$105m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$79m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$7m | US$557k | -US$59m |
| Sep 30 2021 | n/a | n/a | -US$61m |
| Jun 30 2021 | n/a | n/a | -US$53m |
| Mar 31 2021 | n/a | n/a | -US$49m |
| Dec 31 2020 | US$10m | US$521k | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$39m |
| Jun 30 2020 | n/a | n/a | -US$31m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$695k | US$485k | -US$14m |
Compensation vs Market: Jas's total compensation ($USD6.27M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Jas's compensation has been consistent with company performance over the past year.
CEO
Jas Seehra (69 yo)
Dr. Jasbir S. Seehra, also known as Jas, Ph D., is President of Keros Therapeutics, Inc. from August 18, 2025 and has been its Chief Executive Officer and Director since December 2015 and was its Chair of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.1yrs | US$6.27m | 0.99% $ 5.7m | |
| Chief Financial Officer | 5.9yrs | US$2.29m | 0% $ 0 | |
| Senior VP | 5.8yrs | no data | no data | |
| Chief Scientific Officer | less than a year | no data | no data |
Experienced Management: KROS's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.1yrs | US$6.27m | 0.99% $ 5.7m | |
| Independent Director | 5.8yrs | US$386.39k | no data | |
| Independent Chair of the Board | 1.6yrs | US$652.93k | 0.00066% $ 3.8k | |
| Independent Director | 9.8yrs | US$373.60k | 0.0039% $ 22.5k | |
| Independent Director | 5.1yrs | US$382.10k | 0.17% $ 1.0m | |
| Independent Director | 2.7yrs | US$368.81k | 0.11% $ 629.3k | |
| Independent Director | 5.8yrs | US$373.60k | 0.15% $ 851.2k |
Experienced Board: KROS's board of directors are considered experienced (5.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/13 08:41 |
| End of Day Share Price | 2026/01/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keros Therapeutics, Inc. is covered by 18 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Corinne Johnson | Goldman Sachs |
| Andrew Fein | H.C. Wainwright & Co. |